Bausch Health Companies Inc. — Drug Manufacturers - Specialty & Generic. Scored on the same transparent 7-signal model behind the daily rankings.
★
BHC
Bausch Health Companies Inc. · Drug Manufacturers - Specialty & Generic
FCF$1.0bC+
Rev+6.7%C+
D/E——
P/S0.2xA
PEG0.01A
65.5Score
$4.75$1.8B
1Y Target$7.40Analyst consensus · 5 analysts
5Y Target$12.94Compound horizon
10Y Target$32.82Long-dated conviction
FCF$1.0bTTMC+
FCF $1.0b — respectable but not differentiating
Rev+6.7%TTM YoYC+
Revenue +6.7% — steady but below market-beating range
D/E——
D/E data unavailable — neutral default
P/S0.2xA
P/S 0.2x — cheapest decile in Healthcare (≈10th pctile)
PEG0.01A
PEG 0.01 — exceptional; paying well under fair value for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 65.5
Quality0.60
Growth0.54
Value0.86
Why this score
Short track record
Entry · Margin of safety
52-week rangeNear 52-week low
45% off the 12-month high
vs DCF fair value86% belowest. fair value ~$34
What the price assumes: outright free-cash-flow decline for the next decade — vs the ~-5% a year our model projects from current growth and analyst estimates.
Quality signals · context only
Gross profitability33% · B+gross profit ÷ total assets (Novy-Marx)
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.8b. Down 45% from 52-week high of $8.69 — deep drawdown territory. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Hold with a mean 1-yr target of $7.40 (implying +56% upside).
Moat
ROE 59% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -11.5%) — path to GAAP profitability is the core thesis risk. Down 45% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Horizon
1-3 yr $7.40 (5-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $12.94 — requires the platform / technology to reach commercial scale. 10 yr $32.82 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Score history · BHC
Trend
+0.1 over 15 daily scores
From 65.4 (Jun 22) → 65.5 (now)
One point per daily model run. The range autoscales, so a flat-looking line can still hide 1–2 point moves — read the From → To values for the actual range.
Position sizing · BHC
$
%
%
Shares to buy
421
Position size
$2,000
4.0% of portfolio
Stop price
$3.56
25% below $4.75
$ at risk if stopped
$499.94
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Bausch Health Companies Inc. (BHC): score, valuation & FAQ
Bausch Health Companies Inc. (BHC) is a Drug Manufacturers - Specialty & Generic company that scores 65.5 out of 100 on the Bull Rankings quality-growth model — a solid, above-average reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are P/S (A) and PEG (A). On valuation, BHC sits about 86% below our discounted-cash-flow fair value (a margin of safety) — the current price implies outright free-cash-flow decline over the next decade.
Is BHC a good stock to buy?
Bull Rankings scores BHC 65.5 out of 100 on its quality-growth model, which is a solid, above-average reading. That is driven by P/S (A) and PEG (A). A score is a quantitative screen of Bausch Health Companies Inc.'s fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does BHC score 65.5 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). BHC earns its highest marks on P/S (A) and PEG (A). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is BHC overvalued or undervalued?
Based on $4.75, BHC sits about 86% below our discounted-cash-flow fair value (a margin of safety) — the current price implies outright free-cash-flow decline over the next decade. Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in BHC?
Currently unprofitable (margin -11.5%) — path to GAAP profitability is the core thesis risk. Down 45% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.